Filing summary
Entity discrepancy: The supplied filing is for Trovagene, Inc., not Cardiff Oncology, Inc. Verify that this is the intended filing before relying on the figures. It is a Form 10-Q for the quarter ended June 30, 2014, filed August 7, 2014.
Business context and reporting period
Trovagene was developing and commercializing urine-based cell-free DNA mutation testing for cancer monitoring, supported by clinical collaborations. The company reported minimal revenue and no diagnostic-test revenue in the quarter or six-month period.
Financial results and liquidity
| Metric | Three months ended June 30, 2014 | Six months ended June 30, 2014 | Comparable 2013 period |
|---|---|---|---|
| Revenue | $55,628 | $166,581 | $49,000; $168,123 |
| Operating expenses | $3.30 million | $6.67 million | $2.42 million; $4.93 million |
| Operating loss | $3.24 million | $6.50 million | $2.37 million; $4.76 million |
| Net loss attributable to common stockholders | $1.08 million | $4.28 million | $5.28 million; $6.40 million |
| Loss per common share, basic and diluted | $0.06 | $0.23 | $0.34; $0.41 |
At June 30, cash and cash equivalents were $34.67 million, working capital was $33.05 million, total liabilities were $18.86 million, and stockholders’ equity was $17.33 million. Long-term debt, net of discount, was $14.70 million. The company reported $33.6 million of cash at July 31.
For the six months, operating cash use was $5.45 million, versus $3.36 million in 2013; investing cash use was $0.13 million versus $0.36 million. Financing provided $14.42 million, principally from the June debt financing, compared with $1.21 million in the prior-year period. Cash increased by $8.84 million over the six months.
Changes versus the prior comparable periods
- Six-month revenue declined about 1%; second-quarter revenue rose from $49,000 to $55,628, including $10,000 of license fees. The balance was royalty income.
- Six-month operating expenses increased about 35%, led by higher research and development spending as clinical collaborations and staffing expanded. Selling and marketing costs also increased.
- Operating losses widened, but reported net losses improved: a $2.25 million six-month noncash gain from remeasuring warrant-related derivative liabilities significantly reduced the reported loss. The comparable 2013 period had a derivative fair-value loss.
- Weighted-average shares increased to 18.90 million from 15.55 million for the six-month period, reflecting prior stock issuances and exercises of options and warrants.
Outlook, risks, and unusual items
- Capital needs: Management stated in the MD&A that additional capital would be required within 12 months; the liquidity note says within 24 months. The filing does not reconcile these different timeframes. Management cautioned that financing may not be available on acceptable terms and that failure to raise funds could delay, scale back, or stop programs, or lead to unfavorable collaborations or licensing dispositions.
- Debt: In June, the company borrowed $15 million under a loan agreement at 7.07% interest. Interest-only payments run through July 2015, followed by monthly principal and interest payments, with maturity in July 2018. The loan is secured by company assets other than intellectual property, which is subject to a negative pledge; covenants and a $1.05 million final fee also apply. The prior equipment line was paid off.
- Spending and revenue outlook: Management expected research and development, sales and marketing, general and administrative, and interest costs to increase. It gave no quantified revenue or earnings guidance; diagnostic revenue timing and milestone or license revenue were described as uncertain.
- Development and commercialization risks: Clinical validation, regulatory and CLIA requirements, competition, development costs, and access to further capital could affect product timelines and adoption. The company described its product development and commercialization efforts as early-stage.
- Other items: The $2.25 million warrant-liability fair-value gain was noncash and based on significant unobservable inputs (Level 3). A related-party connection existed in a patent assignment and license agreement with GenSignia; the CEO, who was a GenSignia director, did not participate in negotiations and recused himself from the board vote. The agreement generated $10,000 of license-fee revenue in the period. No material pending legal proceedings or material changes to previously disclosed risk factors were reported. Management concluded disclosure controls were effective.
Important facts for investors to verify
- Confirm that the Trovagene 2014 Form 10-Q, rather than a Cardiff Oncology filing, is the intended source.
- Clarify the filing’s differing statements that additional capital is needed within 12 months versus within 24 months, and assess cash runway against ongoing operating cash use.
- Review the $15 million loan’s collateral, covenants, repayment schedule, final fee, and any consequences of covenant breach.
- Separate underlying operating performance from the noncash derivative revaluation gain when assessing the improvement in net loss.
- Track clinical validation, regulatory progress, commercialization, and whether diagnostic revenues materialize; none were reported in these periods.